Want to see HK:2005 full AI Analyst Report?
2005 Stock Chart & Stats
HK$2.68
HK$0.03(1.26%)
At close: 4:00 PM EDT
HK$2.68
HK$0.03(1.26%)
Day’s Range― - ―
52-Week RangeHK$2.01 - HK$3.40
Previous CloseN/A
Volume1.37M
Average Volume (3M)5.65M
Market Cap
HK$7.92B
Enterprise ValueHK$8.55K
Total Cash (Recent Filing)HK$1.82B
Total Debt (Recent Filing)HK$4.01B
Price to Earnings (P/E)15.5
Beta0.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.97%
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,951,113,300
10 Day Avg. Volume4,536,404
30 Day Avg. Volume5,652,093
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.14
Price to Sales (P/S)1.99
P/FCF Ratio27.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.44Price Target Upside28.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable Leverage And Asset GrowthManageable leverage and a growing asset base provide financial resilience and capacity to fund operations or investment. The moderate debt-to-equity range limits balance-sheet strain relative to the company’s substantial equity base, even after the 2025 earnings decline.
Positive Operating Cash FlowPositive operating cash flow through the period and a 2025 free-cash-flow rebound show that the business can generate internal funding. This supports reinvestment and financial flexibility, although the recovery should be monitored because conversion has not been consistent.
Historically Strong ProfitabilityThe company entered the latest downturn with a record of strong profitability: gross margins were about 50–61% and net margins 14–20% during 2020–2024. That historical base suggests established economics, though durability now depends on recovering from 2025 compression.
Bears Say
Revenue And Margin DeteriorationThe 2025 reset affects both demand and unit economics: revenue fell about 9.1% year over year while gross margin dropped to 38.9% and net margin to 11.3%. Sustained weakness would reduce earnings capacity and make prior profitability less representative.
Sharp Decline In Return On EquityReturn on equity fell from roughly 18–19% at its 2022–2024 peak to about 6.4% in 2025. This sharp deterioration indicates weaker earnings power from the existing capital base and could constrain internally funded growth if it persists.
Inconsistent Cash ConversionCash conversion remains uneven: free cash flow was negative in 2024 and, despite recovering to about 300M in 2025, represented only about 47% of net income. Variable working capital or investment needs can limit the reliability of reported profits.
SSY Group News
2005 FAQ
What was SSY Group Limited’s price range in the past 12 months?
SSY Group Limited lowest stock price was HK$2.01 and its highest was HK$3.40 in the past 12 months.
What is SSY Group Limited’s market cap?
SSY Group Limited’s market cap is HK$7.92B.
When is SSY Group Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SSY Group Limited’s earnings last quarter?
Currently, no data Available
Is SSY Group Limited overvalued?
According to Wall Street analysts SSY Group Limited’s price is currently Undervalued.
Does SSY Group Limited pay dividends?
SSY Group Limited pays a Semiannually dividend of HK$0.03 which represents an annual dividend yield of 2.97%. See more information on SSY Group Limited dividends here
What is SSY Group Limited’s EPS estimate?
SSY Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SSY Group Limited have?
SSY Group Limited has 2,951,113,300 shares outstanding.
What happened to SSY Group Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SSY Group Limited?
Currently, no hedge funds are holding shares in HK:2005
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SSY Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$3.44 (28.36% Upside)
HK$3.44 (28.36% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.89%
12-Months-Change
Fundamentals
Return on Equity
2.97%
Trailing 12-Months
Asset Growth
5.37%
Trailing 12-Months
Company Description
SSY Group Limited
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.
2005 Stock 12 Month Forecast
Average Price Target
HK$3.44
▲(28.36% Upside)
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
China Shineway Pharmaceutical Group Limited
―







